Si deseas distinguir tus productos, servicios o ambos de los de otra empresa, es posible que necesites una marca o nombre comercial. Descubre qué son, en qué consiste su procedimiento de registro y qué implica.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Si tienes un nuevo dispositivo, producto o procedimiento que resuelva un problema técnico o tenga una ventaja práctica, existen distintas formas de protegerlo en España y en otros países. Descubre cómo hacerlo.
¿Tu innovación reside en la estética, la ornamentación o la apariencia de tu producto? Protégela mediante un diseño industrial. Descubre qué derechos confiere el registro y cómo realizar la tramitación.
Las indicaciones geográficas protegen el nombre de un producto originario de una zona geográfica, a la cual le debe una determinada calidad, reputación u otra característica. Descubre qué son, en qué consiste su procedimiento de registro y qué beneficios conceden.
Las patentes publicadas en todo el mundo son una valiosa fuente de información científica, técnica y comercial.
Si eres emprendedor/a o una empresa y quieres potenciar y mejorar la rentabilidad de tu negocio protegiendo de forma adecuada los activos intangibles de tu organización, en este espacio encontrarás lo necesario.
345
resultados
Última actualización
04/11/2026 [08:50:00]
Resultados 100 a 125 de 345
Resumen de: CN122901423A
本发明提出了一种基于追踪入肝成分确定肝豆灵治疗WD肝纤维化质量标志物的方法，属于中药复方活性成分鉴定技术领域。首先通过UHPLC‑Orbitrap‑MS检测肝豆灵的体外化学成分和入WD模型大鼠肝组织的原型成分，同时检测WD模型大鼠肝组织作为空白对照，依据“保留时间、峰面积差异倍数FC值>10或者模型组未检出”原则筛选入肝原型成分；然后通过网络药理学和分子对接技术，最终确定阿魏酸、芦荟大黄素、大黄酚等17个成分为肝豆灵治疗WD肝纤维化质量标志物。本发明为阐明肝豆灵治疗WD肝纤维化的药效物质基础、优化质量控制标准及新药开发提供科学的实验依据，为临床用药和新药开发提供了进一步的参考。
Resumen de: CN122901136A
0001 本发明公开了一种检测Aβ42的光纤生物传感器及其制备方法，属于光纤生物传感器技术领域，包括如下步骤：S1、采用无籽生长法制备金纳米三角片，并通过HS‑PEG‑COOH进行配体置换；S2、将单模光纤基体的待加工区域去除涂覆层后进行清洗，采用光纤熔接机对单模光纤基体进行拉锥处理，然后通过CO<2>激光周期性作用，形成TLPG传感器；S3、将TLPG传感器进行表面硅烷化修饰、金纳米三角片负载、羧基活化和抗体固定，得到光纤生物传感器；本发明利用金纳米三角片独特的尖端电场增强与微锥形长周期光纤光栅的倏逝场增强效应协同作用，实现了对Aβ42的高灵敏、快速检测。
Resumen de: CN122882748A
本发明属于生物医药技术领域，公开了一种用于半定量检测生物样本中路易折叠型α‑突触核蛋白病理种子负荷的方法、试剂盒及其应用。本发明首次将α‑突触核蛋白种子扩增技术从定性检测升级为半定量检测：首先进行阳性样本初筛，然后对初筛阳性样本进行基质匹配的系列稀释，结合长时程种子扩增反应，统计所有稀释度复孔的阳性总数，获得路易折叠病理评分。LFP评分与帕金森病患者的Hoehn&Yahr分期、MDS‑UPDRS III运动评分呈正相关，与MoCA认知评分呈负相关，可用于疾病辅助诊断、严重程度辅助评估、进展监测及药效辅助评价。该方法亦可用于检测阿尔茨海默病患者样本中的α‑突触核蛋白种子，为共病理评估提供参考。
Resumen de: CN122878374A
0001 本发明公开了基于PROTAC蛋白靶向降解技术的薯蓣皂素类化合物靶点鉴定方法及PROTAC化合物。本发明以薯蓣皂苷元为靶蛋白配体合成双功能PROTAC分子；通过细胞毒性筛选确定毒性最小的探针，经差异蛋白质组学分析、Western blot、分子对接及CETSA验证确证YTHDF2为作用靶标；通过AD细胞模型验证了薯蓣皂苷通过YTHDF2发挥抗氧化和缓解突突触损伤的作用机制。还提供能够诱导YTHDF2降解的薯蓣皂苷元类PROTAC化合物及其在制备治疗神经退行性疾病药物中的用途。
Resumen de: CN122882751A
本发明公开了一种基于编码微球的弓形虫IgG抗体多指标联检方法。筛选三种低吸附编码微球，分别偶联弓形虫特异性抗原SAG1、MIC3和CST1；优化偶联缓冲液为MEST pH 5.0，抗原标记量降低50%，采用1%BSA+CE210+CE510封闭。样本添加量为5μL，以TBST为清洗液，添加0.2 mg/mL阻断剂和0.01 mg/mL兔抗人IgG‑PE二抗，样本孵育与二抗孵育各15分钟即可完成检测。以健康人群检测结果的均值加3倍标准差作为阳性判断阈值，对弓形虫IgG阳性待测样本进行检测。结果显示，SAG1、MIC3、CST1三个单项抗原的阳性检出率分别为13.56%、16.95%和13.56%，而三联检的阳性检出率提升至32.20%，显著高于任一单项检测。本发明实现了快速、低成本、高灵敏度的弓形虫IgG抗体多指标联检，解决了单一抗原检出率不足的问题。
Resumen de: CN122882754A
本发明提供了缺血性脑卒中生物标志物VTN的检测及应用，属于生物医药技术领域。本发明从高通量蛋白组学筛选、生物信息学精准定位、动物模型验证、大队列临床验证形成完整证据链，系统性揭示外周来源VTN在缺血性脑卒中的诊断价值，该标志物不仅有助于全面阐释缺血性脑卒中的发病机制，还对该疾病的诊断或筛查具备高准确度，具有重要临床应用价值，为缺血性脑卒中的筛查、诊断或疗效评价提供新的技术路径和理论依据。
Resumen de: CN122878457A
本发明提供工程化腺相关病毒AAV衣壳，其中所述衣壳上的至少一种蛋白质被修饰以包含一个n聚体的氨基酸序列取代或插入；用于取代或插入的氨基酸序列如序列表1中SEQ ID NOS:1‑58任一项所示。进一步的实施方案提供了一种载体系统，其包含编码AAV衣壳的一个或多个载体，以及一种向中枢神经系统递送有效载荷的方法。所述方法包括在体内或体外施用根据本文所述实施方案的AAV衣壳，且所述AAV衣壳包含一种或多种有效载荷分子。
Resumen de: US20260309724A1
Methods and compositions for diagnosing brain injury, neurodegeneration; or a predisposition thereto, in a subject are provided. Particularly, the present invention relates to specific antigen antibody reactivities useful in diagnosing brain injury, neurodegeneration or a predisposition thereto, in a subject.
Resumen de: AU2025241870A1
Compositions and methods are disclosed herein for the treatment of Alzheimer's disease with allogeneic mesenchymal stem cells (MSCs). The methods of treatment involve an administration of a composition of allogeneic mesenchymal stem cells to a subject in need thereof, wherein the effectiveness of the treatment methods can be determined through the measurement of specific biomarkers and improved cognitive or quality-of-life function.
Resumen de: US20260309723A1
0000 Methods, systems and kits useful for the detection and diagnosis of neurodegenerative diseases including Alzheimer's Disease (AD)- and early-stage Parkinson's Disease-related pathology, and methods of preparing labeled immunocomplexes useful for detecting AD- and PD-related pathology are provided.
Resumen de: US20260306596A1
0000 The present invention is directed inter alia to the treatment of pain. For example, there is provided a chimeric clostridial neurotoxin for use in treating pain by inhibiting the release of a pain mediator from a neuron comprising an Aδ nerve fiber or a C nerve fiber, wherein the chimeric clostridial neurotoxin binds to the neuron comprising the Aδ nerve fiber or the C nerve fiber, respectively, and wherein the chimeric clostridial neurotoxin comprises a botulinum neurotoxin A (BoNT/A) light-chain and translocation domain (H
Resumen de: US20260308210A1
0000 A polypeptide capable of inhibiting Tau aggregation includes an amino acid sequence sharing between 20% and 99% sequence similarity with a structured core region of a pathological Tau filament, where the polypeptide is capable of binding to an end of a Tau fibril and reducing Tau aggregation or Tau seeding activity. The polypeptide may include an amino acid sequence derived from a microtubule-associated protein such as MAP2 or MAP4. Methods for inhibiting Tau aggregation in a biological sample include contacting the biological sample containing Tau with the polypeptide, where the polypeptide binds to an end of a Tau fibril and reduces Tau aggregation relative to a control sample.
Resumen de: WO2026212334A1
The present invention relates to an immunodiagnostic method using multiple biomarkers, which can improve diagnostic efficiency compared to conventional immunodiagnostic devices. The immunodiagnostic method comprises the steps of: setting a reference range for the level of biomarkers; collecting a human-derived sample from a subject to be tested; measuring two or more biomarkers in the sample so as to be individually identifiable, using detection media capable of distinguishing the biomarkers from each other; and selecting a sample in which the measured level of biomarkers falls outside the reference range.
Resumen de: WO2026209593A1
The present invention is directed to means for assessing whether a subject in need of an anti-amyloid therapy has or develops ARIA-E by determining an amount or a concentration of NfL in a sample of the subject. Further, the present invention relates to the use of NfL in the detection of ARIA-E.
Resumen de: WO2026209594A1
The present invention is directed to means for assessing whether a subject in need of an anti-amyloid therapy has or develops ARIA-E by determining an amount or a concentration of Amyloid-beta 42 (Aβ42) in a sample of the subject. Further, the present invention relates to the use of Aβ42 in the detection of ARIA-E.
Resumen de: US20260309705A1
Provided herein are methods for monitoring treatment for multiple sclerosis in a pregnant subject, and determining the efficacy of a treatment for multiple sclerosis in a pregnant subject. These methods include (a) extracting a drug from a dried blood spot (DBS) sample from a pregnant subject after a treatment for multiple sclerosis has been administered to the pregnant subject; (b) performing mass spectrometry on the extracted DBS sample; (c) determining a peak area ratio of the extracted DBS sample to an internal standard; and (d) identifying the administered treatment as being below the internal standard threshold if the plasma concentration of the treatment is less than 1 as compared to the internal standard ratio. Also provided herein are dried blood spot cards, and kits that include a dried blood spot card pre-treated with at least one internal standard.
Resumen de: US20260309715A1
0000 Provided herein are antibodies binding to LILRB2 and the uses of the antibodies in detecting and treating cancer and autoimmune diseases.
Resumen de: US20260309712A1
Improved antibodies for detection of phosphorylated RBL1, H1.5, LARP6, SUV39H1, and FAM53C have been developed. Assays using them to detect the biomarkers: P-T143 FAM53C, P-T202 LARP6, P-S988 RBL1, P-S17 H1.5, and P-S391 SU-V39H1, and diagnostic and prognostic applications stemming therefrom are also provided.
Resumen de: US20260309725A1
The invention relates to a nasal fluid sample obtained from a subject comprising the marker protein(s) β amyloid (Aβ), phosphorylated Tau (pTau) and/or total Tau (tTau). The invention further relates to a nasal fluid sample comprising the marker protein(s) Aβ, pTau and/or tTau for use in a method for the aid in diagnosis of neurodegenerative diseases and the use of a nasal fluid sample comprising the marker protein(s) Aβ, pTau and/or tTau for the aid in diagnosis of a neurodegenerative disease. The invention further relates to a method for the aid in diagnosis of a neurodegenerative disease in a subject/individual.
Resumen de: US20260309720A1
This invention relates to the detection of Tau protein in body fluids using biomarker peptides and their detection by Multiplexed Liquid Chromatography Tandem Mass Spectrometry (LC-MS/MS) methods such as Selected Reaction Monitoring (SRM). In particular, the biomarker peptides are intended to distinguish between Tau protein produced by the Peripheral Nervous System and Tau protein produced by the Central Nervous System. This invention also relates to methods of using these peptide biomarkers for diagnosing and/or classifying the severity of a Neurodegenerative Disease, treatment of a Neurodegenerative Disease and assessing the efficacy of a treatment for a Neurodegenerative Disease, in particular for Tauopathies such as Alzheimer's disease. Also provided are a kit for diagnosing and/or classifying the severity of a Neurodegenerative disease, a kit for use in the treatment of a Neurodegenerative disease and a kit for assessing the efficacy of a treatment for a Neurodegenerative Disease in a subject.
Resumen de: US20260306484A1
The invention relates to the use of a ROR inverse agonist or a pharmaceutically acceptable salt thereof for the manufacture of a medicament for modulating RORs and/or controlling autoimmune diseases and antibody mediated rejection in a patient. The RORs mediated disease or autoimmune disease includes HIV, cancer, celiac disease, diabetes mellitus type 1, Graves' disease, inflammatory bowel disease, multiple sclerosis, psoriasis, rheumatoid arthritis, systemic lupus erythematosus, asthma, dermatitis, fatty liver disease, Crohn's disease, cardiovascular disease, inflammatory diseases, neurological disorder, multiple sclerosis, acute respiratory distress syndrome and arteriosclerosis.
Resumen de: US20260306439A1
The present disclosure is directed to methods of promoting phagocytosis, particularly the phagocytic activity of microglia via activation of triggering receptor expressed on myeloid cells 2 (TREM2). The present disclosure is also directed to methods of activating TREM2 in a cell, particularly a neuronal cell exhibiting an accumulation of a pathogenic protein. The present disclosure is directed to detecting an effect of a compound on the TREM2 activity as well.
Resumen de: US20260306662A1
0000 Transplantation of inhibitory neuron progenitors rekindles a targeted, time-limited phase of critical period plasticity within recipient brain areas. This restoration of youthful plasticity establishes a therapeutic environment conducive to circuit reorganization, consistently demonstrated to ameliorate cognitive and functional impairments. Remarkably, the mere overexpression of Calb1 in adult inhibitory neurons via viral vectors is adequate to reactivate critical period plasticity without the need for transplantation. Consequently, methodologies and compositions for augmenting Calb1 expression as a therapeutic avenue to reactivate plasticity are described herein.
Resumen de: US20260309718A1
0000 The present invention covers an in vitro method for evaluating the ability of a compound to disrupt or stabilize an interaction between one or more bait and one or more candidate prey in a eukaryotic cell. In addition, the present invention covers compounds identified by the in vitro method according to any one of the preceding claims, for use as a medicament.
Nº publicación: WO2026213117A1 08/10/2026
Solicitante:
THE JOHNS HOPKINS UNIV [US]
THE JOHNS HOPKINS UNIVERSITY
Resumen de: WO2026213117A1
In one aspect, methods for treating a subset of subjects suffering from schizophrenia/schizoaffective disorder exhibiting negative symptoms and/or cognitive deficits that include a) identifying a subject having increased inflammation connected with redox imbalance of olfactory epithelia, and b) treating the identified subject for schizophrenia and/or a schizoaffective disorder. In further aspects, methods of treating subjects with schizophrenia and related psychotic disorders include administration of Nrf2 activators. In further aspects, methods are provided for diagnosing, prognosing, and defining a treatment in response to nasal examination, including Alzheimer's disease and/or cognitive impairment.
BOPI
Sede Electrónica
